Sechenov Medical Journal

Advanced search


Full Text:


Originating from cells of the diffuse neuroendocrine system, neuroendocrine tumors are able to produce biogenic amines and peptide hormones. Due to the significantly different list of biologically active compounds and level of activity of secretory cells in tumor tissues, their clinical manifestations varies. Liver is one of the most frequent targeted organs for metastasizing this type of tumors, regardless of localization. After the patients being diagnosed, all the treatment measures are focused on two aspects. The first is to suppress the clinical symptoms and improve the living quality. The second one, an increase in life expectancy. Among all the potentially effectible treatments, surgical resection is the only one that may radically kill the disease. However, its application are limited in some cases. In this regard, in the strategy of therapeutic approaches of neuroendocrine tumors with metastases in the liver, a combination of medical, surgical and renal surgical methods comes to the fore.

About the Authors

O. V. Chistyakova
N.N. Blokhin Russian Cancer Reseach Center
Russian Federation

O. N. Solovyeva
N.N. Blokhin Russian Cancer Reseach Center
Russian Federation

D. Xiaodong
I.M. Sechenov First Moscow State Medical University
Russian Federation

V. Yu. Kosyrev
I.M. Sechenov First Moscow State Medical University
Russian Federation


1. Williams E.D., Sandler M. The classification of carcinoid tum ours. Lancet 1963; 1: 238-239

2. Modlin I.M., Lye K.D., Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959

3. Rindi G., Klöppel G., Alhman H. et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401

4. Pape U.F., Jann H., Müller-Nordhorn J. et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008; 113:256-265

5. Pavel M., Baudin E., Couvelard A. et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95: 157-176

6. Rindi G., Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. NatRev Endocrinol 2012; 8: 54-64

7. Kleine M., Schrem H., Vondran F.W. et al. Extended surgery for advanced pancreatic endocrine tumours. Br J Surg 2012; 99:88-94

8. Sarmiento J.M., Heywood G., Rubin J. et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197:29-37

9. De Jong M.C., Farnell M.B., Sclabas G. et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg 2010; 252: 142-148

10. Mayo S.C., de Jong M.C., Pulitano C. et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010; 17: 3129-3136

11. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 1998; 66: 1307-1312

12. Ahlman H., Wängberg B., Jansson S. et al. Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion 2000; 62 Suppl 1: 59-68

13. Mazzaglia P.J., Berber E., Milas M., Siperstein A.E. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007; 142: 10-19

14. Elias D., Baton O., Sideris L. et al. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiplecolorectal liver metastases. J Surg Oncol 2005; 90:36-42

15. Demirkan B.H., Eriksson B. Systemic treatment of neuroendocrine tumors with hepatic metastases. Turk J Gastroenterol 2012; 23: 427-437

16. Appetecchia M., Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res 2010; 29: 19

17. Oberg K., Kvols L., Caplin M. et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-973

18. Chua Y.J., Michael M., Zalcberg J.R. et al. Antitumor effect of somatostatin analogs in neuroendocrine tumors. J Clin Oncol 2010; 28: e41-e42; author reply e41-e42

19. Ferone D., Saveanu A., Culler M.D. et al. Novel chimeric somatostatin analogs: facts and perspectives. Eur J Endocrinol 2007; 156 Suppl 1: S23-S28

20. Zhang J., Jia Z., Li Q. et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007; 109: 1478-1486

21. Kulke M.H., Chan J.A., Meyerhardt J.A. et al. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol 2011; 68: 293-300

22. Raymond E., Dahan L., Raoul J.L. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513

23. Raut C.P., Kulke M.H. Targeted therapy in advanced well-differentiated neuroendocrine tumors. Oncologist 2011; 16: 286-295

24. Yao J.C., Shah M.H., Ito T. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N.Engl J Med 2011; 364: 514-523

25. Fjallskog M.L., Janson E.T., Falkmer U.G. et al. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 2008; 88: 53-58

26. Патютко


Views: 216

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2218-7332 (Print)
ISSN 2658-3348 (Online)